17 completed, 1 active not recruiting, 1 terminated, 1 withdrawn. 20 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 20 | Completed 17, Active not recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 1 | 3 | Completed 3 |
| Phase 3 | 1 | Completed 1 |
Follow Kidney Disease: new trials by email Literature Review of Kidney Disease trials Research Report on Kidney Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease Bremelanotide, RAAS inhibition therapy - Kidney Disease | Phase 2 | Completed | Palatin Technologies, Inc | 16 | 2022-12-26 | 2024-10-17 |
| Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKD Nicotinamide riboside - Vascular Diseases, Kidney Disease | Phase 2 | Active not recruiting | University of Colorado, Denver | 118 | 2019-11-19 | 2026-10-02 |
| Clarifying Optimal Sodium Intake Project Sodium Reduction - Blood Pressure, Hypertension | Phase 2 | Completed | University College Hospital Galway | 269 | 2016-04-01 | 2021-04-28 |
| Trial of Oral Glutamine on Mitochondrial Function in CKD First Intervention (14 days), Washout (3 weeks), Second Intervention (14 days) - Cardiovascular Disease, Sarcopenia | Phase 2 | Completed | University of Washington | 11 | 2016-02-25 | 2022-07-14 |
| Preventing Sickle Cell Kidney Disease Losartan - Anemia, Sickle Cell, Sickle Cell Disease | Phase 2 | Terminated | University of Alabama at Birmingham | 1 | 2015-04-01 | 2024-04-03 |
| Effects of PINTA 745 in End Stage Renal Disease (ESRD) Patients Who Require Hemodialysis and Have Protein Energy Wasting PINTA 745, Placebo - End Stage Renal Disease, Kidney Disease | Phase 1 / Phase 2 | Completed | Pinta Biotherapeutics | 51 | 2014-01-01 | 2018-04-11 |
| 42-Day Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia AKB-6548, Placebo - Anemia, Kidney Disease | Phase 2 | Completed | Akebia Therapeutics | 93 | 2011-06-15 | 2022-07-01 |
| Safety and Efficacy Study for AKB-6548 in Participants With Chronic Kidney Disease and Anemia AKB-6548 - Anemia, Kidney Disease | Phase 2 | Completed | Akebia Therapeutics | 10 | 2010-10-21 | 2022-07-01 |
| Repeat Dose Safety and Efficacy Study for Compound to Treat Anemia 1278863A, Placebo - Kidney Disease | Phase 2 | Completed | GlaxoSmithKline | 107 | 2010-03-01 | 2013-11-11 |
| A Trial Comparing Ferumoxytol to Iron Sucrose for the Treatment of Iron Deficiency Anemia in Adult Subjects With Chronic Kidney Disease Ferumoxytol, Iron Sucrose - Iron Deficiency, Anemia | Phase 2 | Completed | AMAG Pharmaceuticals, Inc. | 162 | 2010-03-01 | 2023-07-25 |
| Growth Hormone Secretagogue MK-0677's Effect on Lean Body Mass in Chronic Kidney Disease Stage 4/5 Subjects MK-0677, Placebo - Chronic Kidney Disease, Kidney Disease | Phase 2 | Withdrawn | University of Virginia | 2009-03-01 | 2018-05-14 | |
| Tetrahydrobiopterin in Patients With Chronic Kidney Disease (CKD) and Albuminuria 6R BH4, Vitamin C - Kidney Disease, Albuminuria | Phase 2 | Completed | University of Michigan | 17 | 2008-05-01 | 2016-10-18 |
| Study to Assess Fixed Dosing of AMG 223 in Subjects With Chronic Kidney Disease on Hemodialysis With Hyperphosphatemia AMG 223, Placebo - End Stage Renal Disease, Chronic Kidney Disease | Phase 2 | Completed | Amgen | 167 | 2008-03-01 | 2016-03-14 |
| Chewed vs. Crushed Lanthanum Carbonate in Hemodialysis Patients Lanthanum Carbonate Chewable Product, Lanthanum carbonate crushed powder - Hyperphosphatemia, Kidney Disease | Phase 2 | Completed | University of Illinois at Chicago | 11 | 2008-01-01 | 2020-11-03 |
| Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer Sorafenib - Carcinoma, Renal Cell, Kidney Disease | Phase 2 | Completed | Stanford University | 9 | 2007-12-01 | 2015-06-19 |
| Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients Alemtuzumab, Mycophenolate mofetil, Sirolimus - Kidney Transplantation, Kidney Disease | Phase 1 / Phase 2 | Completed | University of Miami | 9 | 2004-09-01 | 2012-10-02 |
| Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in Adults Alemtuzumab, Sirolimus, Tacrolimus - Kidney Transplantation, Kidney Disease | Phase 1 / Phase 2 | Completed | University of Wisconsin, Madison | 10 | 2003-11-01 | 2018-06-29 |
| Improving Outcomes in Patients With Kidney Disease Due to Diabetes losartan 100 mg orally once daily, spironolactone 25 mg orally once daily, placebo once orally once daily - Diabetes, Kidney Disease | Phase 2 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 92 | 2003-07-01 | 2010-03-02 |
| Using the Drug Spironolactone to Test If It Reduces Protein Leakage From the Kidney Spironolactone, Irbesartan - Kidney Disease, Diabetic Nephropathy | Phase 2 / Phase 3 | Completed | Melbourne Health | 60 | 2002-01-01 | 2005-06-24 |
| Effectiveness of the Investigational Drug Campath-1H in Preventing Rejection of Transplanted Kidneys Alemtuzumab and DSG - Graft Rejection, Kidney Disease | Phase 2 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 5 | 1999-11-01 | 2016-10-27 |
Kidney Diseases (20) · Renal Insufficiency, Chronic (7) · Renal Insufficiency (5) · Anemia (4) · Hypertension (4) · Bronchiolitis Obliterans Syndrome (2) · Cardiovascular Diseases (2) · Kidney Failure, Chronic (2) · Proteinuria (2) · Albuminuria (1) · Anemia, Iron-Deficiency (1) · Anemia, Sickle Cell (1) · Carcinoma, Renal Cell (1) · Diabetes Mellitus (1) · Diabetic Nephropathies (1)
Female Urogenital Diseases (20) · Female Urogenital Diseases and Pregnancy Complications (20) · Male Urogenital Diseases (20) · Urogenital Diseases (20) · Urologic Diseases (20) · Pathological Conditions, Signs and Symptoms (11) · Chronic Disease (8) · Disease Attributes (8) · Pathologic Processes (8) · Renal Insufficiency (6) · Hematologic Diseases (5) · Hemic and Lymphatic Diseases (5) · Signs and Symptoms (4) · Cardiovascular Diseases (3) · Metabolic Diseases (3)
Alemtuzumab (3) · Kidney Transplantation (2) · Losartan (2) · Sirolimus (2) · Spironolactone (2) · Tacrolimus (2) · vadadustat (2) · Acetaminophen (1) · Acyclovir (1) · Angiotensin Receptor Antagonists (1) · Angiotensin-Converting Enzyme Inhibitors (1) · Ascorbic Acid (1) · Clotrimazole (1) · Diphenhydramine (1) · Ferric Oxide, Saccharated (1)
Akebia Therapeutics (2) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2) · AMAG Pharmaceuticals, Inc. (1) · Amgen (1) · GlaxoSmithKline (1) · Melbourne Health (1) · Palatin Technologies, Inc (1) · Pinta Biotherapeutics (1) · Stanford University (1) · University College Hospital Galway (1) · University of Alabama at Birmingham (1) · University of Colorado, Denver (1) · University of Illinois at Chicago (1) · University of Miami (1) · University of Michigan (1)
United States (16) · Australia (2) · India (2) · Belgium (1) · Canada (1) · Germany (1) · Ireland (1) · New Zealand (1) · Poland (1) · Russia (1) · United Kingdom (1)
A. D'jamali, MD, MS (1) · Alan H Lau, Pharm.D. (1) · Andrew Smyth, MB PhD (1) · Christopher Haqq, MD, PhD (1) · Dr. Sandy Srinivas (1) · Gavin G Becker, MBBS MD (1) · George W. Burke, III, MD (1) · James Tumlin, MD (1) · Jeffrey D Lebensburger, DO, MSPH (1) · Jonathan Himmelfarb, MD (1) · Martin J O'Donnell, MB PhD MRCPI (1) · Michel Chonchol, MD (1)
PMID 33107592, PMID 36005278, PMID 23903014, PMID 24408116, PMID 24458078, PMID 27388615, PMID 28343225, PMID 36348660, PMID 36749631, PMID 37064508, PMID 38682786, PMID 40576086, PMID 41264372
2009 (1), K23DK099442 (1), K23HL127100 (1), R01DK121516 (1)